<DOC>
	<DOCNO>NCT01489709</DOCNO>
	<brief_summary>This study evaluate effect Vesicare quality life ( QOL ) female patient .</brief_summary>
	<brief_title>Post Marketing Survey Vesicare Japan</brief_title>
	<detailed_description>Overactive bladder ( OAB ) represent constellation symptom must include urinary urgency essential symptom diagnosis . It usually accompany daytime frequency nighttime frequency ( urgency incontinence essential symptom ) impair patient 's activity daily live quality life ( QOL ) . The objective survey confirm QOL improvement patient treat Vesicare ( Generic Name : solifenacin succinate ) , use OAB-q ( Overactive bladder questionnaire ) , questionnaire assessment OAB symptom QOL . The effect improvement OAB symptom solifenacin QOL also confirm . This survey include male OAB patient since many benign prostatic hyperplasia coexist disease QOL suppose affected Î±1-blocker treatment . To define patient 's response solifenacin term QOL clearly , survey include female OAB patient .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Previously untreated OAB patient Patients meet diagnostic criterion OAB provide clinical guideline overactive bladder ( patient urinary urgency least weekly essential symptom least one OAB symptom include daytime frequency , nighttime frequency , urgency incontinence ) Patients understand answer OABq ( Japanese version ) Patients data item concern OABSS , OABq , satisfaction score urination obtain baseline Patients expect treat least 12 week</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>overactive bladder</keyword>
	<keyword>solifenacin</keyword>
	<keyword>Overactive bladder questionnaire</keyword>
	<keyword>Overactive Bladder Symptom Score</keyword>
	<keyword>satisfaction score</keyword>
</DOC>